Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa–Levodopa
Aravind Mittur, Suneel Gupta, Nishit B. Modi
Clinical Pharmacokinetics (2017) Vol. 56, Iss. 9, pp. 999-1014
Open Access | Times Cited: 46

Showing 26-50 of 46 citing articles:

State-of-the art pharmacotherapy for non-neovascular age-related macular degeneration
Daniele Veritti, Valentina Sarao, Francesco Samassa, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 7, pp. 773-784
Closed Access | Times Cited: 13
Differential Gait Decline in Parkinson’s Disease Enhances Discrimination of Gait Freezers from Non-Freezers
Aliyah Glover, Lakshmi Pillai, Shannon Doerhoff, et al.
Journal of Parkinson s Disease (2020) Vol. 10, Iss. 4, pp. 1657-1673
Open Access | Times Cited: 12
Treatment of Parkinson's Disease
Deepmala Nandanwar, Daniel Truong
Elsevier eBooks (2024)
Closed Access | Times Cited: 1
Therapeutic drug monitoring in Parkinson’s disease
Thomas Müller, Manfred Gerlach, Gudrun Hefner, et al.
Journal of Neural Transmission (2024)
Closed Access | Times Cited: 1
Patient-specific in vitro drug release testing coupled with in silico PBPK modeling to forecast the in vivo performance of oral extended-release levodopa formulations in Parkinson’s disease patients
Erik Wollmer, Sandra Klein
European Journal of Pharmaceutics and Biopharmaceutics (2022) Vol. 180, pp. 101-118
Closed Access | Times Cited: 6
Objective impairment of tandem gait in Parkinson's disease patients increases with disease severity
Rohan Sharma, Lakshmi Pillai, Aliyah Glover, et al.
Parkinsonism & Related Disorders (2019) Vol. 68, pp. 33-39
Open Access | Times Cited: 9
Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation
Nishit B. Modi
The AAPS Journal (2017) Vol. 19, Iss. 3, pp. 607-618
Closed Access | Times Cited: 6
Adverse effects of medications used to treat motor symptoms of Parkinson's disease: A narrative review
Pettarusp M. Wadia, Bhushan Mishal, Akash Shetty
Annals of Movement Disorders (2023) Vol. 6, Iss. 2, pp. 45-57
Open Access | Times Cited: 2
Drugs Acting on Central Nervous System
Dipesh Chakraborty, Ria Das
(2024), pp. 89-121
Closed Access
Multicolorimetric Sensor Array Based on Silver Metallization of Gold Nanorods for Discriminating Dopaminergic Agents
Reza Koohsar, Afsaneh Orouji, M. Reza Hormozi‐Nezhad
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 19, pp. 3513-3524
Closed Access
Machine Learning-Empowered Multicolor Detection and Discrimination of Dopaminergic Agents: Utilizing Gold Nanorods for Generating Rainbow Signals
Zahra Hozhabr, Afsaneh Orouji, M. Reza Hormozi‐Nezhad
ACS Applied Nano Materials (2024)
Closed Access
The macrocyclic lactones ivermectin and moxidectin show differential effects on rotational behavior in the 6-hydroxydopamine mouse model of Parkinson’s disease
Alicia M. P. Warnecke, Moon Sung Kang, Michael W. Jakowec, et al.
Behavioural Brain Research (2020) Vol. 393, pp. 112804-112804
Open Access | Times Cited: 3
Management of OFF condition in Parkinson disease
Jessa Koch
Mental Health Clinician (2023) Vol. 13, Iss. 6, pp. 289-297
Open Access | Times Cited: 1
A study of the genotoxicity, fertility and early embryonic development toxicity of rotigotine behenate extended‐release microspheres
Xinyu Zhao, Chunmin Guo, Hong Zhang, et al.
Basic & Clinical Pharmacology & Toxicology (2023) Vol. 134, Iss. 3, pp. 361-373
Closed Access | Times Cited: 1
Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey
Robert A. Hauser, Ghazal Banisadr, Kara Vuong, et al.
Parkinson s Disease (2021) Vol. 2021, pp. 1-9
Open Access | Times Cited: 3
Medical treatment of the motor features of Parkinson disease
Joseph Jankovic, Mark Hallett, Michael S. Okun, et al.
Elsevier eBooks (2021), pp. 164-203.e14
Closed Access | Times Cited: 2
Drug Delivery Strategies in Parkinson’s Disease
Gurpreet Singh, Anupama Sikder, Shashi Bala Singh, et al.
(2023), pp. 305-324
Closed Access
Pharmacokinetic Evaluation of Chitosan Coated Hydroxypropylmethyl Cellulose (HPMC) Microparticles of Levodopa and Carbidopa
Benedicta Obenewaa Dankyi
(2019)
Closed Access
Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson’s Disease
Thomas Müller
Springer eBooks (2020), pp. 1-18
Closed Access
Movement Disorders
Tsao‐Wei Liang
Cambridge University Press eBooks (2022), pp. 218-234
Closed Access
Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson’s Disease
Thomas Müller
Springer eBooks (2022), pp. 2853-2870
Closed Access
Therapeutic and Diagnostic Agents for Parkinson's Disease
Ola A.M. Ghoneim, Raymond G. Booth
Burger's Medicinal Chemistry and Drug Discovery (2021), pp. 1-46
Closed Access
Previous Page - Page 2

Scroll to top